TME Pharma N.V. ALTME
EURONEXT · Fransa · Sağlık Teknolojisi
€0,1034-0,00 (-%0,77)
Piyasa kapalı· · EUR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · EUR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today publishes a message from its CEO for the shareholders. Dear Shareholders,As I look back on the recent period, one clear feeling dominates: remained confidence in the path we are taking. We fully understand that many of you are eager to see concrete
TME Pharma provides update on its activities TME Pharma enters the final evaluation phase of advanced discussions with two potential partners for a license agreement.Discussions and potential partnership are aimed at enabling the further development of the phase2-development of flagship product NOX-A12.NOX-A12 holds FDA and EU Orphan Drug and FDA Fast Track designations in glioblastoma, supported by recent peer-reviewed publication in Nature Communications.With estimated yearly peak sales potent
Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today announced that all resolutions were adopted at the meeting held on June 15. The Annual General Meeting of TME Pharma shareholders was held on Monday, June 15, 2026, chaired by Mr. Diede van den Ouden. Four shareholders were
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.